Central Bank of Jordan Selects BIO-key for National Biometric Authentication Initiative
Central Bank of Jordan Selects BIO-key for National Biometric Authentication, Aiming to Advance Biometric Authentication Across Jordan's Financial Sector
BIO - Bio-Rad Laboratories, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$321.67
DETAILS
HIGH:
$335.00
LOW:
$310.00
MEDIAN:
$320.00
CONSENSUS:
$321.67
DOWNSIDE:
2.82%
Stock News
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
Bio-Rad Laboratories Inc (BIO) Stock Up 3.4% and Still Undervalued -- GF Score: 72/100
On July 23, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 3.4%, bringing the current price to $316.38. The stock has exhibited a 52-week range between $236.7
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2026 on Tuesday, August 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful conclusion of YD Bio's and its affiliate EG BioMed Co., Ltd.'s (“EG BioMed”) participation at BIO Asia-Taiwan 2026, an international industry conference held in Taiwan, at the Washington State Pavilion on July 19, 2026.
Assetmark Inc. Raises Stock Holdings in Bio-Rad Laboratories, Inc. $BIO
Assetmark Inc. boosted its stake in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 19.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,989 shares of the medical research company's stock after purchasing an additional 6,224 shares during the quarter.
Noveris Health Sciences Joins the Biotechnology Innovation Organization (BIO)
VANCOUVER, BC, Canada – TheNewswire - July 17, 2026 — Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) (“Noveris” or the “Company”) is pleased to announce that it has joined the Biotechnology Innovation Organization (“BIO”), the world's largest advocacy association representing biotechnology companies, academic and research institutions, state and regional biotechnology centers and related organizations across the United States and in more than 35 other countries. By joining BIO, Noveris is strengthening its participation in the global biotechnology ecosystem and expanding opportunities to engage with industry leaders, strategic partners, investors and policymakers across the United States and internationally. The Company believes that membership in BIO will support greater visibility for Noveris within the broader biotechnology and life sciences community while providing access to BIO's policy committees, investor and partnering events, industry research and cost-savings programs that help foster collaboration and commercialization.
BIO-key Regains Compliance with Nasdaq Listing Rules; Nasdaq Trading Resumes on Wednesday, July 8th
HOLMDEL, N.J., July 07, 2026 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management and biometric authentication technologies, today announced that The Nasdaq Stock Market LLC has notified it that the trading of its common stock will recommence on the Nasdaq Capital Market effective with markets' opening on Wednesday, July 8, 2026.
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced its participation in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026.
BIO-key Showcases Passwordless & Biometric Identity Solutions at Jordan Banking Cybersecurity Workshop in Amman on July 6th
BIO-key (BKYI) a global leader in biometric-powered identity & access management to participate at Jordan Banking Cybersecurity Workshop in Amman, July 6.
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential
I assign a "Buy" rating to Bio-Rad Laboratories, citing activist involvement. Elliott's entry signals meaningful re-rating potential, assuming further operational improvements; BIO is already shifting M&A focus to revenue-generating bolt-ons and rationalizing R&D spend. The potential monetization of BIO's Sartorius stake, worth over $5 billion, appears more likely with Elliott's involvement, since the activist is also a shareholder of Sartorius.
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 6.5% Rally? GF Value Says Undervalued
On June 25, 2026, Bio-Rad Laboratories Inc (BIO) shares rose 6.5% to $298.29. This movement comes in the context of a 52-week range between $235.01 and $343.12,
HKSTP Leads Largest-Ever Hong Kong Delegation to BIO 2026 Showcasing Life and Health Tech Strength
41 local tech firms, institutes and university spin-offs head to San Diego to forge global partnerships, reinforcing the city's status as international healthcare innovation hub HONG KONG SAR/SAN DIEGO, UNITED STATES - Media OutReach Newswire - 24 June 2026 - Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK as co-organiser, the Hong Kong Trade Development Council (HKTDC) as supporting organisation, and five renowned local universities - The University of Hong Kong, The Chinese University of Hong Kong, The Hong Kong University of Science and Technology, The Hong Kong Polytechnic University and City University of Hong Kong - to form the city's largest-ever delegation of life and health technology innovators to the BIO International Convention 2026 (BIO 2026) in San Diego, from June 22 to 25. In collaboration with InvestHK and HKTDC, HKSTP led a delegation of 41 park companies, institutes and spin-offs from five renowned local universities to showcase the Hong Kong's life and health technology innovations at BIO 2026 in San Diego. Building on last year's momentum, the 2026 Hong Kong delegation doubled the size of the Hong Kong Pavilion, expanding to a record of 41 organisations from HKSTP, including partner companies, research institutes, and for the first time with top five universities spin-offs. This landmark presence showcased Hong Kong's deep strength across AI-enabled biotech, therapeutics, diagnostics, and pharma innovation, with potential outstanding "First-in-Class" and "Best-in-Class" assets. The delegation underscores the city's leading role as Asia's largest and the world's second largest fundraising hub for the biotechnology sector. Mr. Terry Wong, CEO of HKSTP, said, "BIO 2026 is a premier platform to showcase Hong Kong's groundbreaking innovation, deepen partnerships, and open new pathways into global healthcare markets. As a super-connector, Hong Kong is uniquely positioned to bridge global innovators with opportunities across Asia and beyond. With strong R&D capabilities backed by world-class universities—five ranked among the QS Top 100, including two with medical schools now placed in the global top 20—Hong Kong's biotech and medical research excellence is increasingly recognised worldwide. As the city's innovation ecosystem orchestrator, HKSTP brings together talent, capital, research institutions, clinical partners, and industry leaders to accelerate the journey from discovery to impact. We will continue to empower life and health technology ventures, translating innovation breakthroughs into life-changing solutions that benefit communities around the world." HKSTP and P ark Companies A dvanced in C ross-border I nnovation and M arket E xpansion A key highlight of BIO 2026 is witnessing the signing of three major strategic partnerships: LabCentral -- HKSTP signed an MOU with one of the largest global non - profit biotech incubators, supporting life sciences startups with high-impact lab infrastructure and scientific community programmes. The collaboration will deepen ties between the U.S. and Hong Kong life sciences ecosystems through startup support, ecosystem engagement, and co-developed programmes, events and strategic initiatives. It will also help connect startups, investors, corporate partners and research institutions, creating stronger pathways for cross-border innovation and commercialisation. Immuno Cure – the developer of the first-in-human novel therapeutic HIV vaccine ICVAX – announced its collaboration with OPIS, an international Contract Research Organization (CRO), at BIO 2026. Leveraging OPIS's full-service, multi-country clinical trial expertise and regulatory knowledge, the partnership will support overseas clinical trial execution and establish a global framework to prepare for international expansion. Zhaoke Ophthalmology signed an MOU with Laboratório Teuto, the first company to produce generic medicines and OTCs (Over the Counter – Prescription Exempt Medicines) in Brazil, to explore cross-border cooperation in ophthalmology. This is Zhaoke's first strategic MOU in Brazil market. Leveraging its innovative pipeline and Teuto's commercial network in Brazil, the partnership aims to bring advanced eye care treatments to Latin American patients while demonstrating the globalisation of Hong Kong-born biotech innovation. Beyond the BIO 2026 Hong Kong Pavilion, HKSTP CEO Mr Terry Wong attended the "Translating Innovation Across Borders: Creating Global Gateways for Biotech Startups" panel sharing session. Mr. Wong shared his insights on cutting-edge biotech trends, Hong Kong's strengths on life and health tech development, and HKSTP's role in building a global bridge for nurturing global startup expansion, sustainable innovation and collaboration. Furthermore, HKSTP and five Hong Kong university delegates visited the Salk Institute, home to six Nobel Laureates during BIO 2026 to explore partnerships and shape global biotech momentum through collaborative platforms. HKSTP, in collaboration with InvestHK as co-organiser, HKTDC as the supporting organisation, and powered by the Hong Kong Economic and Trade Office in San Francisco, hosted a Global Mixer during the exhibition. Industry leaders, incubators, and venture capital firms – including Bayer Pharmaceuticals, Johnson & Johnson Innovation, LabCentral, Roche, Simcere Pharmaceutical, and T.Rx Capital – were invited to join the judging panel for startup pitching sessions. The Pavilion also featured executive sharing and curated networking events for commercialisation, licensing, partnerships, investment and international market expansion. Global recognition at Biomedical Pitch Competition In the lead-up to BIO 2026, HKSTP actively drove engagement across the biotech sector and co-organised the 2026 Biomedical Pitch Competition with the Boston Capital Investment Club in Boston on May 23 and 24. Competing against around 170 biotechnology companies worldwide, HKSTP park company Meta Pharmaceuticals (HK) Limited won Third Place for its next-generation autoimmune therapeutics. The recognition underscores the strength of Hong Kong's biotech pipeline and HKSTP's commitment to translational medicine, commercialisation and globally scalable healthcare solutions. HK's biotech ecosystem rises to another level Hong Kong continues to expand its global healthcare footprint as the world's second-largest biotech fundraising hub. As Hong Kong's flagship innovation and technology ecosystem, HKSTP is home to more than 300 life and health technology companies and helps innovators turn pioneering ideas into real-world impact. Its ecosystem connects capital, talent, infrastructure and market access across the biotech innovation journey. Hashtag: #HKSTPThe issuer is solely responsible for the content of this announcement. Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 17,000 research professionals and over 2,500 technology companies from 26 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at www.hkstp.org.
BIO CEO says more consistency needed in FDA review process
U.S. biotechnology industry trade group BIO worked with the Food and Drug Administration on plans announced on Monday to speed clinical trials and expects the next initiative will aim to standardize the agency's review of drug applications, CEO John Crowley said on Tuesday.
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026?
Bio-Rad Laboratories offers high profitability and a liquid balance sheet with a current ratio above 5x. Charles River Laboratories International maintains a leading scale in drug discovery services with over 19,000 employees globally.
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the 2026 BIO International Convention taking place this week in San Diego, California.
CJ BIO to Showcase TasteNrich® Taste Lab for Sodium Reduction, Clean Label, and Taste Design Solutions at IFT FIRST 2026
"Not Just Reducing, But Designing Better Taste" CHICAGO and DOWNERS GROVE, Ill., June 22, 2026 /PRNewswire/ -- CJ BIO will participate in IFT FIRST 2026, taking place July 13–15, 2026, at McCormick Place in Chicago.
Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development and AI-Enabled Research at BIO International 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase new capabilities, strategic investments and initiatives at BIO International 2026 that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster. Spanning AI-enabled research, clinical development and advanced manufacturing, these investments reinforce Thermo Fisher's role as a trusted strategic provider of integrated.
New Mexico Bioscience Delegation Showcases Innovation and Industry Growth at BIO International Convention 2026
Albuquerque, NM, June 18, 2026 (GLOBE NEWSWIRE) -- A delegation of economic development, research, healthcare, and industry leaders will represent New Mexico's growing bioscience sector at the BIO International Convention, taking place June 22–25, 2026, in San Diego, California. Led by the Albuquerque Regional Economic Alliance (AREA), the delegation will promote New Mexico's bioscience industry, highlight the state's innovation ecosystem, and connect with companies, investors, and industry leaders from around the globe.
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026
President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present Company's vision for transforming women's health President and CEO, Sabrina Martucci Johnson, to participate in featured industry panels and present Company's vision for transforming women's health
Price Targets
Bio-Rad price target raised to $310 from $290 at Wells Fargo
$310.00
(was $287.74)
Wells Fargo
Bio-Rad resumed with an Outperform at RBC Capital
$320.00
(was $246.27)
RBC Capital
Bio-Rad price target lowered to $290 from $320 at Wells Fargo
$290.00
(was $280.12)
Wells Fargo
Bio-Rad price target lowered to $320 from $340 at Wells Fargo
$320.00
(was $256.56)
Brandon Couillard
·
Wells Fargo
Bio-Rad price target lowered to $335 from $350 at UBS
$335.00
(was $259.64)
UBS
Bio-Rad price target raised to $340 from $265 at Wells Fargo
$340.00
(was $319.47)
Wells Fargo
Citi Upgrades Bio-Rad Labs (BIO) to Buy
$400.00
(was $338.58)
Patrick Donnelly
·
Citigroup
RBC Capital Initiates Coverage On Bio-Rad Laboratories with Outperform Rating, Announces Price Target of $565
$565.00
(was $399.59)
RBC Capital